ArticleACS medicinal chemistry letters2015
SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of
Abstract read
In one paragraph
Article in ACS medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Therapeutic Antitoxoplasmosis Potential ofJournal of tropical medicine · 2026Article
- Design, synthesis, and anti-Toxoplasma gondii evaluation of β-carboline derivatives.Parasites & vectors · 2025Article
- Concurrent Assessment of Synthetic and Natural Compounds on the Proliferation ofTropical medicine and infectious disease · 2025Article
- Anti-Cryptosporidium efficacy of BKI-1708, an inhibitor of Cryptosporidium calcium-dependent protein kinase 1.PLoS neglected tropical diseases · 2025Article
- Identification of Coumarin-Chalcone and Coumarin-Pyrazoline Derivatives as Novel Anti-Drug design, development and therapy · 2024Article
- Employing Hexahydroquinolines asAdvances and applications in bioinformatics and chemistry : AABC · 2024Article
- A screen of drug-like molecules identifies chemically diverse electron transport chain inhibitors in apicomplexan parasites.PLoS pathogens · 2023Article
- Photoswitchable Inhibitors to Optically Control Specific Kinase Activity.ACS chemical biology · 2023Article
- In vitro maturation of Toxoplasma gondii bradyzoites in human myotubes and their metabolomic characterization.Nature communications · 2022Article
- One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases.Veterinary parasitology · 2021Review
- Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned.International journal for parasitology · 2020Review
- Treatment with Bumped Kinase Inhibitor 1294 Is Safe and Leads to Significant Protection against Abortion and Vertical Transmission in Sheep Experimentally Infected with Toxoplasma gondii during Pregnancy.Antimicrobial agents and chemotherapy · 2019Article
- Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis.The Journal of infectious diseases · 2019Article
- Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.Journal of medicinal chemistry · 2019Article
- Plasmodial Kinase Inhibitors: License to Cure?Journal of medicinal chemistry · 2018Article
- Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays.Antimicrobial agents and chemotherapy · 2018Article
- Safety and efficacy of the bumped kinase inhibitor BKI-1553 in pregnant sheep experimentally infected with Neospora caninum tachyzoites.International journal for parasitology. Drugs and drug resistance · 2018Article
- In vitro growth inhibition of Theileria equi by bumped kinase inhibitors.Veterinary parasitology · 2018Article
- The calcium-dependent protein kinase 1 from Toxoplasma gondii as target for structure-based drug design.Parasitology · 2018Review
- In vitro efficacy of bumped kinase inhibitors against Besnoitia besnoiti tachyzoites.International journal for parasitology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Wenlin HuangDepartment of Biochemistry, University of Washington , Seattle, Washington 98195, United States.
Kayode K OjoDepartment of Medicine, Division of Allergy and Infectious Diseases, and the Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington , Seattle, Washington 98109, United States.
Zhongsheng ZhangDepartment of Biochemistry, University of Washington , Seattle, Washington 98195, United States.
Kasey RivasDepartment of Medicine, Division of Allergy and Infectious Diseases, and the Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington , Seattle, Washington 98109, United States.
Rama Subba Rao VidadalaDepartment of Chemistry, University of Washington , Seattle, Washington 98195, United States.
Suzanne ScheeleCenter for Infectious Disease Research (formerly Seattle Biomedical Research Institute), Seattle, Washington 98109, United States.
Amy E DeRocherCenter for Infectious Disease Research (formerly Seattle Biomedical Research Institute), Seattle, Washington 98109, United States.
Ryan ChoiDepartment of Medicine, Division of Allergy and Infectious Diseases, and the Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington , Seattle, Washington 98109, United States.
Matthew A HulversonDepartment of Medicine, Division of Allergy and Infectious Diseases, and the Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington , Seattle, Washington 98109, United States.
Lynn K BarrettDepartment of Medicine, Division of Allergy and Infectious Diseases, and the Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington , Seattle, Washington 98109, United States.
Igor BruzualPortland VA Medical Center , Portland, Oregon 97239, United States.
Latha Kallur SiddaramaiahDepartment of Biochemistry, University of Washington , Seattle, Washington 98195, United States.
Keshia M KerchnerDepartment of Biochemistry, University of Washington , Seattle, Washington 98195, United States.
Matthew D KurnickAbbVie , N. Chicago, Illinois 60064, United States.
Gail M FreibergAbbVie , N. Chicago, Illinois 60064, United States.
Dale KempfAbbVie , N. Chicago, Illinois 60064, United States.
Wim G J HolDepartment of Biochemistry, University of Washington , Seattle, Washington 98195, United States.
Ethan A MerrittDepartment of Biochemistry, University of Washington , Seattle, Washington 98195, United States.
Georg NeckermannPATH , San Francisco, California 94102, United States.
Eugenio L de HostosPATH , San Francisco, California 94102, United States.
Nina IsoherranenDepartment of Pharmaceutics, University of Washington , Seattle, Washington 98195, United States.
Dustin J MalyDepartment of Chemistry, University of Washington , Seattle, Washington 98195, United States.
Marilyn ParsonsCenter for Infectious Disease Research (formerly Seattle Biomedical Research Institute), Seattle, Washington 98109, United States ; Department of Global Health, University of Washington , Seattle, Washington 98195, United States.
J Stone DoggettPortland VA Medical Center , Portland, Oregon 97239, United States.
Wesley C Van VoorhisDepartment of Medicine, Division of Allergy and Infectious Diseases, and the Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington , Seattle, Washington 98109, United States ; Department of Global Health, University of Washington , Seattle, Washington 98195, United States.
Erkang FanDepartment of Biochemistry, University of Washington , Seattle, Washington 98195, United States.
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MCalcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvumR01AI089441 · NIAID · UNIVERSITY OF WASHINGTON · PI MERRITT, ETHAN A, PARSONS, MARILYN · 2010 to 2014
$5.0MDevelopment of the potent anti-malarial and anti-Toxoplasma drug, ELQ-316IK2BX002440 · VA · PORTLAND VA MEDICAL CENTER · PI DOGGETT, JOSEPH STONE · 2014 to 2018
–BLRD VA IK2 BX002440NIAID NIH HHS R01 AI089441NIH HHS P51 OD011132
Abstract
We previously discovered compounds based on a 5-aminopyrazole-4-carboxamide scaffold to be potent and selective inhibitors of CDPK1 from
Indexed as
calcium-dependent protein kinase-1enzyme inhibitorstructure−activity relationship studiesToxoplasma gondii
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.